Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Profibrotic role of myostatin in Peyronie's disease.

Cantini LP, Ferrini MG, Vernet D, Magee TR, Qian A, Gelfand RA, Rajfer J, Gonzalez-Cadavid NF.

J Sex Med. 2008 Jul;5(7):1607-22. doi: 10.1111/j.1743-6109.2008.00847.x.

PMID:
18422491
2.

Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model.

Vernet D, Ferrini MG, Valente EG, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF.

Nitric Oxide. 2002 Dec;7(4):262-76.

PMID:
12446175
3.

The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Gelfand RA, Vernet D, Kovanecz I, Rajfer J, Gonzalez-Cadavid NF.

J Sex Med. 2015 Feb;12(2):313-27. doi: 10.1111/jsm.12760. Epub 2014 Dec 11.

4.

Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.

Davila HH, Ferrini MG, Rajfer J, Gonzalez-Cadavid NF.

BJU Int. 2003 Jun;91(9):830-8.

5.

L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures.

Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF.

Nitric Oxide. 2003 Dec;9(4):229-44.

PMID:
14996430
6.

Evidence that osteogenic progenitor cells in the human tunica albuginea may originate from stem cells: implications for peyronie disease.

Vernet D, Nolazco G, Cantini L, Magee TR, Qian A, Rajfer J, Gonzalez-Cadavid NF.

Biol Reprod. 2005 Dec;73(6):1199-210. Epub 2005 Aug 10.

7.

Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque.

Piao S, Choi MJ, Tumurbaatar M, Kim WJ, Jin HR, Shin SH, Tuvshintur B, Yin GN, Song JS, Kwon MH, Lee SJ, Han JY, Kim SJ, Ryu JK, Suh JK.

J Sex Med. 2010 Oct;7(10):3385-95. doi: 10.1111/j.1743-6109.2010.01753.x.

PMID:
20233292
8.

Experimental models of Peyronie's disease. Implications for new therapies.

Gonzalez-Cadavid NF, Rajfer J.

J Sex Med. 2009 Feb;6(2):303-13. doi: 10.1111/j.1743-6109.2008.01104.x. Epub 2008 Dec 2. Review.

PMID:
19138365
9.

Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease.

Ferrini MG, Kovanecz I, Nolazco G, Rajfer J, Gonzalez-Cadavid NF.

BJU Int. 2006 Mar;97(3):625-33.

10.

Silencing histone deacetylase 2 using small hairpin RNA induces regression of fibrotic plaque in a rat model of Peyronie's disease.

Kwon KD, Choi MJ, Park JM, Song KM, Kwon MH, Batbold D, Yin GN, Kim WJ, Ryu JK, Suh JK.

BJU Int. 2014 Dec;114(6):926-36. doi: 10.1111/bju.12812. Epub 2014 Aug 13.

11.

Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease.

Davila HH, Magee TR, Vernet D, Rajfer J, Gonzalez-Cadavid NF.

Biol Reprod. 2004 Nov;71(5):1568-77. Epub 2004 Jul 7.

12.

Upregulation of monocyte chemoattractant protein 1 and effects of transforming growth factor-beta 1 in Peyronie's disease.

Lin CS, Lin G, Wang Z, Maddah SA, Lue TF.

Biochem Biophys Res Commun. 2002 Jul 26;295(4):1014-9.

PMID:
12127997
13.

Estradiol attenuates the TGF-β1-induced conversion of primary TAFs into myofibroblasts and inhibits collagen production and myofibroblast contraction by modulating the Smad and Rho/ROCK signaling pathways.

Jiang HS, Zhu LL, Zhang Z, Chen H, Chen Y, Dai YT.

Int J Mol Med. 2015 Sep;36(3):801-7. doi: 10.3892/ijmm.2015.2288. Epub 2015 Jul 16.

PMID:
26179216
14.

Peyronie's disease associated with increase in plasminogen activator inhibitor in fibrotic plaque.

Davila HH, Magee TR, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF.

Urology. 2005 Apr;65(4):645-8.

PMID:
15833499
15.

Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease.

Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Kim H, Trost LW, Kadowitz PJ, Abdel-Mageed AB, Sikka SC, Hellstrom WJ.

Andrology. 2014 Mar;2(2):244-51. doi: 10.1111/j.2047-2927.2013.00181.x.

16.

Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease.

Piao S, Ryu JK, Shin HY, Zhang L, Song SU, Han JY, Park SH, Kim JM, Kim IH, Kim SJ, Suh JK.

Int J Androl. 2008 Jun;31(3):346-53. Epub 2007 Jul 25.

PMID:
17651407
17.

Mechanisms of penile fibrosis.

Gonzalez-Cadavid NF.

J Sex Med. 2009 Mar;6 Suppl 3:353-62. doi: 10.1111/j.1743-6109.2008.01195.x. Review.

PMID:
19267860
18.

Intratunical Injection of Genetically Modified Adipose Tissue-Derived Stem Cells with Human Interferon α-2b for Treatment of Erectile Dysfunction in a Rat Model of Tunica Albugineal Fibrosis.

Gokce A, Abd Elmageed ZY, Lasker GF, Bouljihad M, Braun SE, Kim H, Kadowitz PJ, Abdel-Mageed AB, Sikka SC, Hellstrom WJ.

J Sex Med. 2015 Jul;12(7):1533-44. doi: 10.1111/jsm.12916. Epub 2015 Jun 10.

19.

Pentoxifylline attenuates transforming growth factor-β1-stimulated collagen deposition and elastogenesis in human tunica albuginea-derived fibroblasts part 1: impact on extracellular matrix.

Shindel AW, Lin G, Ning H, Banie L, Huang YC, Liu G, Lin CS, Lue TF.

J Sex Med. 2010 Jun;7(6):2077-85. doi: 10.1111/j.1743-6109.2010.01790.x. Epub 2010 Mar 30.

20.

The anti-inflammatory and antifibrosis effects of anthocyanin extracted from black soybean on a Peyronie disease rat model.

Sohn DW, Bae WJ, Kim HS, Kim SW, Kim SW.

Urology. 2014 Nov;84(5):1112-6. doi: 10.1016/j.urology.2014.06.026. Epub 2014 Aug 22.

PMID:
25156514
Items per page

Supplemental Content

Write to the Help Desk